Aptose Biosciences (TSE:APS) has released an update. Aptose Biosciences is advancing the development of its promising drug tuspetinib as part ...

Researchers sought to determine whether DNA methylation markers could be helpful in risk stratification for patients with AML and normal cytogenetics.

The authors note that while many genomic studies over the years have helped scientists classify AML subtypes, the genomic profiles and biomarkers among diverse patients with AML are under studied.

The AML program must include the following minimum ... relationships for the purpose of developing a customer risk profile and (2) identify and report suspicious transactions and, on a risk ...

On 10/10/24, FinCEN assessed a record $1.3 billion penalty against TD Bank for BSA violations. This unprecedented penalty ...

AML HQ [1], a standalone product built to automate routine anti-money laundering (AML) tasks and allow accounting and bookkeeping firms to make ...

A layman reading the latest anti-money-laundering (AML) figures [1] issued by the Institute of Chartered Accountants in England and Wales (ICAEW) might ...

With the continuous implementation of rigorous AML programmes and real-time monitoring ... More details on BitMEX's transformation of its risk profile is available via a Chainalysis case study ...

Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly ...

Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The ...